{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:13:47Z","timestamp":1788848027645,"version":"build-2803163510"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2019,11,1]]},"DOI":"10.1001\/jamadermatol.2019.2610","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T11:31:04Z","timestamp":1568201464000},"page":"1284","source":"Crossref","is-referenced-by-count":57,"title":["Incidence of Long-term Opioid Use Among Opioid-Naive Patients With Hidradenitis Suppurativa in the United States"],"prefix":"10.1001","volume":"155","author":[{"given":"Sarah","family":"Reddy","sequence":"first","affiliation":[{"name":"Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, New Hyde Park, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.V.","family":"Orenstein","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Strunk","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, New Hyde Park, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, New Hyde Park, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"doi190047r1","article-title":"Evaluating unmet needs in hidradenitis suppurativa: results from the Global VOICE project","author":"Garg","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi190047r2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2340\/00015555-2815","article-title":"Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa.","volume":"98","author":"Matusiak","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"doi190047r3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process.","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi190047r6","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1373\/49.4.624","article-title":"LOINC, a universal standard for identifying laboratory observations: a 5-year update.","volume":"49","author":"McDonald","year":"2003","journal-title":"Clin Chem"},{"issue":"4","key":"doi190047r7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/amiajnl-2011-000116","article-title":"Normalized names for clinical drugs: RxNorm at 6 years.","volume":"18","author":"Nelson","year":"2011","journal-title":"J Am Med Inform Assoc"},{"issue":"9","key":"doi190047r8","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jamainternmed.2016.3298","article-title":"Incidence of and risk factors for chronic opioid use among opioid-na\u00efve patients in the postoperative period.","volume":"176","author":"Sun","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"1","key":"doi190047r9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000468148","article-title":"Validation of a case-finding algorithm for hidradenitis suppurativa using administrative coding from a clinical database.","volume":"233","author":"Strunk","year":"2017","journal-title":"Dermatology"},{"issue":"6","key":"doi190047r10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/AJP.0b013e318169d03b","article-title":"De facto long-term opioid therapy for noncancer pain.","volume":"24","author":"Von Korff","year":"2008","journal-title":"Clin J Pain"},{"issue":"7","key":"doi190047r11","doi-asserted-by":"publisher","first-page":"504","DOI":"10.7326\/M18-2261","article-title":"Risk and risk factors for chronic opioid use among opioid-na\u00efve patients with newly diagnosed musculoskeletal pain in the neck, shoulder, knee, or low back.","volume":"170","author":"Moshfegh","year":"2018","journal-title":"Ann Intern Med"},{"key":"doi190047r14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1472-6963-12-18","article-title":"Validation of key behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use.","volume":"12","author":"Kim","year":"2012","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"doi190047r15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jaad.2018.02.053","article-title":"Opioid, alcohol, and cannabis misuse among patients with hidradenitis suppurativa: a population-based analysis in the United States.","volume":"79","author":"Garg","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi190047r16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jamadermatol.2015.4593","article-title":"Factors associated with point-of-care treatment decisions for hidradenitis suppurativa.","volume":"152","author":"Garg","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"4","key":"doi190047r17","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/bjd.2009.161.issue-4","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity.","volume":"161","author":"Sartorius","year":"2009","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi190047r18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaad.2014.04.001","article-title":"Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity.","volume":"71","author":"Schrader","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"20","key":"doi190047r19","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1001\/archinte.163.20.2433","article-title":"Depression and pain comorbidity: a literature review.","volume":"163","author":"Bair","year":"2003","journal-title":"Arch Intern Med"},{"issue":"19","key":"doi190047r20","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1001\/archinte.166.19.2087","article-title":"Association between mental health disorders, problem drug use, and regular prescription opioid use.","volume":"166","author":"Sullivan","year":"2006","journal-title":"Arch Intern Med"},{"issue":"2","key":"doi190047r21","article-title":"Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice.","volume":"6","author":"Fuentes","year":"2018","journal-title":"Pharmacy (Basel)"},{"issue":"2","key":"doi190047r22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.pain.2008.04.027","article-title":"Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study.","volume":"138","author":"Sullivan","year":"2008","journal-title":"Pain"},{"issue":"6","key":"doi190047r27","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/bjd.13163","article-title":"The hidradenitis suppurativa priority setting partnership.","volume":"171","author":"Ingram","year":"2014","journal-title":"Br J Dermatol"},{"issue":"23","key":"doi190047r28","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1001\/jama.2018.18472","article-title":"Opioids for chronic noncancer pain: a systematic review and meta-analysis.","volume":"320","author":"Busse","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"doi190047r30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016.","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"doi190047r31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.2015.29.issue-4","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa.","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"doi190047r32","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jaad.2015.07.046","article-title":"Pain management in patients with hidradenitis suppurativa.","volume":"73","author":"Horv\u00e1th","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi190047r33","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1370\/afm.1371","article-title":"Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuse.","volume":"10","author":"Grattan","year":"2012","journal-title":"Ann Fam Med"},{"key":"doi190047r34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1472-6963-6-46","article-title":"Predictors of opioid misuse in patients with chronic pain: a prospective cohort study.","volume":"6","author":"Ives","year":"2006","journal-title":"BMC Health Serv Res"},{"issue":"10","key":"doi190047r35","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/j.1360-0443.2010.03052.x","article-title":"Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system.","volume":"105","author":"Boscarino","year":"2010","journal-title":"Addiction"},{"issue":"6","key":"doi190047r36","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1526-4637.2005.00072.x","article-title":"Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool.","volume":"6","author":"Webster","year":"2005","journal-title":"Pain Med"},{"issue":"9","key":"doi190047r37","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpain.2006.03.001","article-title":"The DIRE score: predicting outcomes of opioid prescribing for chronic pain.","volume":"7","author":"Belgrade","year":"2006","journal-title":"J Pain"},{"issue":"1-2","key":"doi190047r38","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.pain.2007.01.014","article-title":"Development and validation of the Current Opioid Misuse Measure.","volume":"130","author":"Butler","year":"2007","journal-title":"Pain"},{"key":"doi190047r4","unstructured":"IBM Watson Health. The data curation process: Watson Health informatics overview of mapping, standardization, and indexing. https:\/\/www.ibm.com\/downloads\/cas\/JBNOXQK4. Published June 2016. Accessed July 14, 2019."},{"key":"doi190047r5","unstructured":"US National Library of Medicine Unified Medical Language System (UMLS). Systematized Nomenclature of Medicine\u2014Clinical Terms (SNOMED CT). http:\/\/www.nlm.nih.gov\/research\/umls\/Snomed\/snomed_main.html. Reviewed May 23, 2018. Accessed July 14, 2019."},{"key":"doi190047r12","unstructured":"Centers for Disease Control and Prevention. Opioid overdose: analyzing prescription data and morphine milligram equivalents (MME). Atlanta, GA: Centers for Disease Control and Prevention; 2018. https:\/\/www.cdc.gov\/drugoverdose\/resources\/data.html. Updated April 10, 2019. Accessed July 14, 2019."},{"key":"doi190047r13","unstructured":"US Department of Justice, Drug Enforcement Administration, Office of Diversion Control. Practioner\u2019s manual: an informational outline of the Controlled Substances Act. https:\/\/www.deadiversion.usdoj.gov\/pubs\/manuals\/pract\/pract_manual012508.pdf. 2006 edition. Accessed July 14, 2019."},{"key":"doi190047r23","unstructured":"FrenkSM, PorterK, PaulozziLJ. Prescription opioid analgesic use among adults: United States, 1999-2012. NCHS Data Brief. No.189. https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db189.pdf. Published February 2015. Accessed July 14, 2019."},{"key":"doi190047r24","unstructured":"United States Environmental Protection Agency. Fact sheet for OSCs: fentanyl and fentanyl analogs, version 1.0. https:\/\/www.epa.gov\/sites\/production\/files\/2018-07\/documents\/fentanyl_fact_sheet_ver_7-26-18.pdf. Published May 22, 2018. Accessed July 14, 2019."},{"key":"doi190047r25","unstructured":"HedegaardH, BastianBA, TrinidadJP, WarnerM. Drugs most frequently involved in drug overdose deaths: United States, 2011-2016. National Vital Statistics Reports, Vol 67, No. 9. https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr67\/nvsr67_09-508.pdf. Published December 12, 2018. Accessed July 14, 2019."},{"key":"doi190047r26","unstructured":"World Health Organization. Tramadol: update review report: agenda item 6.1. Expert Committee on Drug Dependence; Thirty-Sixth Meeting; Geneva, Switzerland. https:\/\/www.who.int\/medicines\/areas\/quality_safety\/6_1_Update.pdf. June 16-20, 2014. Accessed July 14, 2019."},{"key":"doi190047r29","unstructured":"World Health Organization. Cancer pain relief with a guide to opioid availability. 2nd ed. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/37896\/9241544821.pdf?sequence=1&isAllowed=y. Published 1996. Accessed July 14, 2019."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2749768\/jamadermatology_reddy_2019_oi_190047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T11:01:05Z","timestamp":1573642865000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2749768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2019.2610","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,1]]}}}